Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib in combination with FOLFIRI for the...

Related Keywords

Germany ,Munich ,Bayern ,Lunresertib Lunre ,Zeva Wainberg ,Repare Therapeutics Inc ,European Society Of Medical Oncology ,Linkedin ,Twitter ,Gastrointestinal Gi Cancers Congress ,Company Nasdaq ,David Geffen School Of Medicine ,Repare Therapeutics ,European Society ,Medical Oncology ,Cancers Congress ,Advanced Gastrointestinal ,David Geffen School ,